|03/05/19||Luminex Corporation to Present at the Barclays Global Healthcare Conference|
|AUSTIN, Texas, March 5, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 12-14, 2019, in Miami.
The fireside chat will begin at 9:30 a.m. Eastern time on Tuesday, March 12, 2019. The fireside chat will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the About Luminex section and ... |
|02/08/19||Luminex Corporation Declares First Quarter Cash Dividend|
|AUSTIN, Texas, Feb. 8, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of 2019 of $0.06 per share of common stock payable on April 11, 2019 to stockholders of record as of the close of business March 21, 2019.
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range o... |
|02/04/19||Luminex Corporation Reports Fourth Quarter and Full-Year 2018 Financial Results|
|AUSTIN, Texas, Feb. 4, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2018. Financial and operating highlights for the quarter and full-year include:
On December 31, 2018, the Company closed the acquisition of EMD Millipore Corporation's flow cytometry portfolio for $69.9 million in cash, plus approximately $5.1 million in committed inventory purchases.
Fourth quarter and full-year 2018 consolidated rev... |
|01/07/19||Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2018; Company to Present at 37th Annual J.P. Morgan Healthcare Conference|
|AUSTIN, Texas, Jan. 7, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2018 to be approximately $81 million and to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million.
Select fourth quarter highlights include:
Total Licensed Technologies Group revenue grew 23% to more than $41 million, compared to the fourth quarter of 2017
|01/02/19||Luminex Corporation Completes Acquisition of MilliporeSigma's Flow Cytometry Portfolio|
|AUSTIN, Texas, Jan. 2, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined stock, asset and inventory purchases. The acquisition is expected to contribute $40 million to $50 million in revenue to Luminex in 2019.
"We are pleased to announce the completion of this transaction and excited to welcome the talented MilliporeSigma flow cytome... |